Biosimilars Don't Deserve Unique Name, Group Tells FDA

By Emily Atkin (September 20, 2013, 8:02 PM EDT) -- A major generic pharmaceutical industry group told the U.S. Food and Drug Administration on Thursday not to give unique names to generic versions of biologic drugs, saying identical names for branded biologics and their biosimilars would not confuse customers or create drug safety concerns as some fear....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!